Health ❯Healthcare

Drug Development

Mergers and Acquisitions Neurology Research Regulatory Affairs Urinary Tract Infections Infectious Diseases Epidemiology Investment Analysis Medical Innovations Opioid Crisis

Sanofi to Acquire Blueprint Medicines for $9.1 Billion, Boosting Its Rare Immunology Pipeline

The Q3 closing will add Blueprint’s FDA-approved systemic mastocytosis therapy Ayvakit alongside late-stage candidates to Sanofi’s portfolio.

Mixed Phase 3 Outcomes Cloud Future of Regeneron and Sanofi’s COPD Candidate Itepekimab

MIT-Harvard Study Identifies New Alzheimer’s Drug Targets in RNA and DNA Pathways

Researchers Uncover Brain Ion Channel's Role in Molecular Memory

Researchers Identify Broad-Spectrum Inhibitors for Malaria Parasite's Key Protein Family

Study Reveals Sex-Based Protein Differences Driven by Non-Genetic Factors

Eli Lilly Reports Record Q1 Revenue but Faces Profit Pressure and Competitive Challenges

Zongertinib Achieves Breakthrough in Treating HER2-Mutant Lung Cancer

UK Grants First Global Approval for GSK’s Blenrep in Two Combination Therapies

FDA Launches Immediate Plan to Replace Animal Testing with Human-Relevant Methods

FDA Launches Roadmap to Phase Out Animal Testing in Drug Development

FDA Approves First New Oral Antibiotic for UTIs in Over 20 Years

Eli Lilly Launches Mounjaro in India to Address Obesity and Diabetes

Novo Nordisk's CagriSema Falls Short in Latest Weight-Loss Trial for Diabetes Patients

Sanofi and J&J Halt E. coli Vaccine Trial After Insufficient Efficacy

FDA Approves Journavx, First Non-Opioid Painkiller in Over 20 Years

Novo Nordisk's Amycretin Shows 22% Weight Loss in Trial, Boosting Stock